ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2026
[Mechanism of NUF2 in Promoting NSCLC Progression through the Regulation of Ferroptosis].
Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNUF2 component of NDC80 kinetochore complex (NUF2) is a core regulatory protein that ensures proper chromosome segregation, and its aberrant expression is closely associated with cancer initiation and progression. Although the expression level of NUF2 is higher in non-small cell lung cancer (NSCLC) than in normal tissues, its mechanism of action in NSCLC remains unclear. This study aims to investigate the mechanism by which NUF2 promotes the proliferation, migration, and invasion of NSCLC.
methodsThe expression differences of NUF2 between NSCLC and normal lung tissues as well as the correlation between NUF2 expression and overall survival (OS) of NSCLC patients were analyzed via the Gene Expression Profiling Interactive Analysis (GEPIA) database. Immunohistochemical (IHC) staining was performed to detect the positive expression rate of NUF2 in NSCLC specimens. NUF2 knockdown and overexpression stable cell lines were established in the A549 cell line, and transfection efficiency was verified by Western blot (WB) and quantitative real-time polymerase chain reaction (RT-qPCR). The proliferation, migration, and invasion of transfected cells were assessed using the cell counting kit-8 (CCK-8), colony formation assay, wound healing assay, and Transwell assay. The expression levels of ferroptosis-related proteins were determined using WB and RT-qPCR. Commercial assay kits were utilized to measure the contents of malondialdehyde (MDA), reactive oxygen species (ROS), ferrous ion (Fe²+) and glutathione (GSH), while intracellular mitochondrial structural alterations were visualized by transmission electron microscopy (TEM). Xenograft tumor models were established. The expression levels of NUF2, SLC7A11 and ACSL4 were detected by WB, RT‑qPCR and IHC.
resultsGEPIA analysis revealed that NUF2 was significantly highly expressed in NSCLC (P<0.05) and was associated with OS (P<0.001). Clinical statistical analyses demonstrated that upregulated NUF2 was significantly associated with advanced clinical stage (P<0.05) and lymph node metastasis (P<0.01). NUF2 knockdown markedly suppressed the proliferation, migration and invasion of NSCLC cells (P<0.001) and reduced xenograft tumor volume in vivo (P<0.05). Mechanistically, NUF2 silencing downregulated the expression of the ferroptosis master regulator SLC7A11 (P<0.01) while upregulating ACSL4 (P<0.01). The levels of MDA (P<0.01), ROS and Fe²+ (P<0.001) were all elevated following NUF2 knockdown, while the content of GSH decreased (P<0.001). TEM observation revealed that NUF2 knockdown led to mitochondrial shrinkage, reduced cristae number and increased membrane density. Conversely, NUF2 overexpression enhanced NSCLC cell proliferation, migration and invasion (P<0.001) and increased xenograft tumor volume (P<0.001). Meanwhile, SLC7A11 expression was elevated (P<0.01) and ACSL4 expression was decreased (P<0.01). The levels of ROS (P<0.001), MDA and Fe²+ were decreased (P<0.01), and the GSH level was increased (P<0.01).
conclusionsNUF2 is highly expressed in NSCLC and is closely associated with poor prognosis and lymph node metastasis. NUF2 inhibits ferroptosis by upregulating SLC7A11 expression and downregulating ACSL4 expression, thereby promoting the proliferation, migration, and invasion of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.